These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19490600)

  • 1. Antibody engineering to develop new antirheumatic therapies.
    Isaacs JD
    Arthritis Res Ther; 2009; 11(3):225. PubMed ID: 19490600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 3. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.
    Campbell J; Lowe D; Sleeman MA
    Br J Pharmacol; 2011 Apr; 162(7):1470-84. PubMed ID: 21182494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. New therapeutic target for rheumatoid arthritis.].
    Nanki T
    Clin Calcium; 2018; 28(5):637-641. PubMed ID: 29731458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis.
    Chen SJ; Lin GJ; Chen JW; Wang KC; Tien CH; Hu CF; Chang CN; Hsu WF; Fan HC; Sytwu HK
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for rheumatoid arthritis.
    Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2006 Dec; 6(12):1349-60. PubMed ID: 17223742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis].
    Mugnier B; Bouvenot G
    Rev Med Interne; 2000 Oct; 21(10):854-62. PubMed ID: 11075394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
    Thurlings RM; Vos K; Gerlag DM; Tak PP
    Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New treatments for rheumatoid arthritis].
    Girault V; Flipo RM
    Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of protein therapeutics by directed evolution.
    Vasserot AP; Dickinson CD; Tang Y; Huse WD; Manchester KS; Watkins JD
    Drug Discov Today; 2003 Feb; 8(3):118-26. PubMed ID: 12568781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
    Timlin H; Bingham CO
    Expert Opin Biol Ther; 2014 Jul; 14(7):893-904. PubMed ID: 24720727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis.
    Braun J; Kalden JR
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S164-7. PubMed ID: 19822066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
    Edwards JC; Leandro MJ; Cambridge G
    Rheum Dis Clin North Am; 2004 May; 30(2):393-403, viii. PubMed ID: 15172048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of biological agents in the treatment of rheumatoid arthritis.
    Fan PT; Leong KH
    Ann Acad Med Singap; 2007 Feb; 36(2):128-34. PubMed ID: 17364080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for patients with rheumatoid arthritis.
    Oliver S; Mooney J
    Prof Nurse; 2002 Aug; 17(12):716-20. PubMed ID: 12229045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody treatments for rheumatoid arthritis.
    Bossaller L; Rothe A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1257-72. PubMed ID: 23789825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
    Combe B; van Vollenhoven R
    Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.